 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- AGX323 / Angex Pharma
[VIRTUAL] AGX323 - A SAM-competitive, orally available inhibitor of protein arginine methyltransferase 5 (PRMT5) with potent cellular antiproliferative and in vivo antitumor activity against selected solid cancer types () - Mar 11, 2021 - Abstract #AACR2021AACR_1967;
AGX323 demonstrated potentially best-in-class activity in PRMT5 dependent human solid cancer models and exhibited excellent drug-like properties. IND enabling studies are currently planned.